Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay

MT Newswires Live

Apr 01

Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer

cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.

The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.

The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.

The company's shares rose nearly 3% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2624636785"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624636785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624636785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624636785","market":"sg","top_or_hot":-1,"title":"Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-01 10:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALA.AU","symbol_name":"AROVELLA THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624636785","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624636785","pubTimestamp":1775011349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor , which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T  cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALA.AU":"AROVELLA THERAPEUTICS LTD","BK4022":"陆运","BK4539":"次新股","BK7096":"制药","CAR":"安飞士","BK4230":"旅客陆运","BK7503":"科技股","BK7002":"互动媒体与服务","BK4139":"生物科技","CAR.AU":"CAR GROUP LTD","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"Arovella Therapeutics在体外试验中证实了靶向Claudin 18.2的CAR抗胰腺癌、胃癌的功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALA.AU":1,"LENZ":1.5,"CAR":1.5,"CAR.AU":1},"content_text":"Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}